Examples of using Combination with melphalan in English and their translations into Dutch
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
The most commonly observed adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone are:
A 2.12-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide(9 cycles) in combination with melphalan and prednisone(1.57 per 100 person-years)
was not increased as compared to thalidomide in combination with melphalan and prednisone 0.79 per 100 person-years.
The following table 5 describes safety data from 340 patients with previously untreated multiple myeloma who received VELCADE(1.3 mg/ m2) in combination with melphalan(9 mg/ m2) and prednisone(60 mg/ m2) in a prospective Phase III study.
sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion ILP.
multicentre study have demonstrated a survival advantage when thalidomide is used in combination with melphalan and prednisone for 12 cycles of 6 weeks in the treatment of newly diagnosed multiple myeloma patients.
compared to thalidomide in combination with melphalan and prednisone 1.19 per 100 person-years.
sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion ILP.
In these patients, Velcade is used in combination with melphalan and prednisone(other medicines for multiple myeloma); patients whose disease is progressive(getting worse)
The clinically important adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone or dexamethasone include:
has been observed in patients receiving lenalidomide in combination with melphalan and prednisone until progression(1.75 per 100 person-years)
for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic ILP.
of 682 patients was conducted to determine whether bortezomib(1.3 mg/m2 injected intravenously) in combination with melphalan(9 mg/m2)
of 682 patients was conducted to determine whether VELCADE(1.3 mg/m2 injected intravenously) in combination with melphalan(9 mg/m2)
Thalidomide Celgene' s benefits are greater than its risks, in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged greater than or equal to 65 years or ineligible for high dose chemotherapy.
of 682 patients was conducted to determine whether VELCADE(1.3 mg/ m2) in combination with melphalan(9 mg/ m2)
of 682 patients was conducted to determine whether VELCADE(1.3 mg/ m2) in combination with melphalan(9 mg/ m2)
In combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation. in combination with the medicines dexamethasone
Table 1: Starting doses for thalidomide in combination with melphalan and prednisone.
Table 2: Recommended posology for Bortezomib Accord in combination with melphalan and prednisone.